Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations
Authors:
Hana Vošmiková; Aleš Ryška; Kateřina Sieglová; Jan Laco
Authors‘ workplace:
Fingerlandův ústav patologie LF UK a FN, Hradec Králové
Published in:
Čes.-slov. Patol., 52, 2016, No. 4, p. 210-214
Category:
Reviews Article
Overview
Development of targeted cancer therapy is accompanied by a search for markers allowing prediction of response to the particular treatment. Recently, the interest is focused, among other neoplasms, also on the therapy of ovarian cancer using new inhibitors of poly (ADP-ribose) polymerase (PARP) proteins, nuclear enzymes involved in the repair of single-stranded DNA breaks. The greatest benefit from the administration of PARP inhibitors have patients with a deleterious or potentially deleterious germ-line or somatic mutation of BRCA1 or BRCA2, two genes responsible for repair of double stranded DNA breaks. There has been described a wide spectrum of mutations of BRCA 1/2, from point substitutions to large deletions, including sometimes even several exons of the gene.
Unlike the testing of germ-line mutations provided for many years by the medical geneticists, somatic mutations in the tumor tissue have not been routinely tested so far. Detection of BRCA1/2 mutations in the tumor is significantly different from testing of germ-line mutations. In comparison with the analysis of DNA isolated from blood samples, testing of DNA isolated from the FFPE tissue encounters challenges based on heterogeneous representation of tumor cells in the tissue samples, on the presence of multiple neoplastic clones and on the infiltration of tissue by the non-neoplastic elements, as well as difficulties caused by variable proportion of apoptotic and necrotic cells deteriorating the overall quality of isolated DNA.
Regarding the testing methods, NGS appears to be the optimal choice because of its complexity, speed of implementation into routine diagnostics as well as sensitivity for detection of a BRCA 1/2 mutations. When introduced into everyday laboratory practice, the functioning quality control system is of utmost importance. Provided there is a high probability of detection of the so far unreported variations in BRCA 1/2 genes, an introduction of a shared database of somatic variants diagnosed in the Czech Republic would be of enormous benefit.
Keywords:
BRCA1 – BRCA2 – ovarian cancer – FFPE – DNA sequencing – next generation sequencing – NGS
Sources
1. National Comprehensive Cancer Network. Ovarian Cancer (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf
2. Vyzula R, et al. Modrá Kniha České onkologické společnosti, 2016, 22. vydání, http://www.linkos.cz/files/modra-kniha/15.pdf
3. Ledermann J, Harter P, Gourley Ch, et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. N Engl J Med 2012; 366: 1382-1392.
4. Ledermann J, Harter P, Gourley Ch, et al. Olaparib maintenance therapy in patiens with platinum sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis ofoutcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852–861.
5. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266 (5182): 66-71.
6. Smith TM, Lee MK, Szabo CI, et al. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res 1996; 6: 1029-1049.
7. Tavtigian S, Simard J, Rommens J, et al. The complete BRCA 2 gene and mutations in chromosome 13q-linked kindreds. Nature Genetics 1996; 12: 333 – 337.
8. Plevová P, Novotný J, Petráková K, et al. Syndrom hereditárního karcinomu prsu a ovarií. Klin Onkol 2009; 22(Suppl): S8– S11.
9. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8: 17.
10. Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly(ADPRibose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28(22): 3570-3576.
11. Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20(3): 764-775.
12. Foretová L, Macháčková E, Palácová M, et al. Doporučení rozšíření indikačních kriterií ke genetickému testování mutací v genech BRCA1 a BRCA2 u hereditárního syndromu nádorů prsu a ovarií. Klin Onkol 2016; 29(Suppl 1): 9–13.
13. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010; 10: 685-696.
14. Cree IA, Deans Z, Ligtenberg MJL, et al. Guidance for laboratories performing molecular pathology for cancer patients. J ClinPathol 2014; 0: 1–9.
15. Gilbert MTP, Haselkorn T, Bunce M, et al. The Isolation of Nucleic Acids from Fixed, Paraffin-Embedded Tissues–Which Methods Are Useful When? PLoS ONE 2007; 2(6): e537.
16. Koubková L, Vojtěšek B, Vyzula R. Sekvenování nové generace a možnosti jeho využití v onkologické praxi. Klin Onkol 2014; 27(Suppl 1): 61–68.
17. Singh RR, Luthra R. Validation and Implementation of Next- Generation Sequencing Technologies in a Clinical Molecular Diagnostic Laboratory. In: Wu W, Choudhry H. Next Generation Sequencing in Cancer Research (Volume 2). Springer; 2015: 127-135.
18. Endris V, StenzingerA,Pfarr N, et al. NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial. Virchows Arch 2016; 468: 697–705.
19. Froňková E. Sekvenování nové generace. Cesk Patol 2013; 49(3): 129–132.
20. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nature Reviews Genetics2016; 17: 333–351.
21. Ellison G, Huang S, Carr H, et al. A reliable method for the detection of BRCA1 and BRCA2 mutations in fixed tumour tissue utilising multiplex PCR-based targeted next generation sequencing. BMC Clinical Pathology 2015; 15: 5.
22. Sims D, Sudbery I, Ilott NE, et al. Sequencing depth and coverage: key considerations in genomic analyses. Nat Rev Genet 2014; 15(2):121-32.
23. Wood HM, Belvedere O, Conway C, et al. Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens. Nucleic Acids Res 2010; 38(14): e151.
24. Wong SQ, Li J, Salemi R, et al. Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. Sci Rep 2013; 3: 3494.
25. Grasso C, Butler T, Rhodes K, et al. Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. J Mol Diagn 2015; 17(1): 53-63.
26. Hogervorst FBL, Nederlof PM, Gille JJP, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Research 2003; 63: 1449–1453.
27. White SJ, Vink GR, Kriek M, et al. Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses. Hum Mutat 2004; 24: 86-92.
28. Kwong A, Chen J, Shin VY, et al. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Cancer Genetics 2015; 208: 448–454.
29. Krejčí A, Müller P, Vojtěšek B. Bioinformatika a sekvenování nové generace. KlinOnkol 2015; 28 (Suppl 2): 2S91–2S96.
30. www.idbrca.com/content/dam/website-services/global/brca/255-idbrca-com/assets/pdfs/bioinformatics-white-paper-complete-nov-2015.pdf
31. Wallis Y, Payne S, McAnulty C, et al. Practice guidelines for the evaluation of pathogenicity and the reporting of sequence variants in clinical molecular genetics. http://www.acgs.uk.com/
32. Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008; 29(11): 1282-1291.
Labels
Anatomical pathology Forensic medical examiner ToxicologyArticle was published in
Czecho-Slovak Pathology
2016 Issue 4
Most read in this issue
- Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations
- Diffuse tenosynovial giant cell tumor of the cervical spine destroying vertebra C6 - a case report
- BRCA1 and BRCA2 – pathologist’s starting kit
- Breast cancer in BRCA1/2 mutation carriers